MX2022015277A - Composiciones y metodos para la edicion de genes. - Google Patents
Composiciones y metodos para la edicion de genes.Info
- Publication number
- MX2022015277A MX2022015277A MX2022015277A MX2022015277A MX2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A MX 2022015277 A MX2022015277 A MX 2022015277A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- gene editing
- genomes
- manipulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033397P | 2020-06-02 | 2020-06-02 | |
| US202063114850P | 2020-11-17 | 2020-11-17 | |
| US202163171698P | 2021-04-07 | 2021-04-07 | |
| PCT/US2021/035244 WO2021247570A2 (en) | 2020-06-02 | 2021-06-01 | Compositions and methods for gene editing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015277A true MX2022015277A (es) | 2023-02-13 |
Family
ID=78831704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015277A MX2022015277A (es) | 2020-06-02 | 2021-06-01 | Composiciones y metodos para la edicion de genes. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240309345A1 (https=) |
| EP (1) | EP4158009A4 (https=) |
| JP (1) | JP2023529611A (https=) |
| KR (1) | KR20230031832A (https=) |
| AU (1) | AU2021283185A1 (https=) |
| CA (1) | CA3184884A1 (https=) |
| GB (2) | GB2637278B (https=) |
| IL (1) | IL298434A (https=) |
| MX (1) | MX2022015277A (https=) |
| WO (1) | WO2021247570A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3227103A1 (en) | 2021-07-30 | 2023-02-02 | Matthew P. GEMBERLING | Compositions and methods for modulating expression of frataxin (fxn) |
| US20240252684A1 (en) | 2021-07-30 | 2024-08-01 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| GB2625500B (en) | 2021-09-21 | 2026-04-01 | Scribe Therapeutics Inc | Engineered CasX repressor systems |
| IL316722A (en) * | 2022-05-01 | 2024-12-01 | Chroma Medicine Inc | Compositions and methods for epigenetic regulation of PCSK9 expression |
| GB2634837A (en) * | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| JP2025524455A (ja) * | 2022-06-23 | 2025-07-30 | エヌクロマ・バイオ，インコーポレーテッド | Ｔｒａｃ発現のエピジェネティック調節のための組成物及び方法 |
| IL317701A (en) * | 2022-06-23 | 2025-02-01 | Chroma Medicine Inc | Epigenetic editing compositions and methods |
| EP4544058A1 (en) * | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of ciita expression |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
| CA3260110A1 (en) | 2022-06-24 | 2023-12-28 | European Molecular Biology Laboratory | MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI |
| CA3261865A1 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS |
| KR20250077608A (ko) * | 2022-08-19 | 2025-05-30 | 튠 쎄라퓨틱스, 인코포레이티드 | 표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법 |
| WO2024044574A1 (en) * | 2022-08-23 | 2024-02-29 | The Regents Of The University Of California | Compositions and methods for reducing ionizing radiation-induced hematopoietic stem cell damage |
| WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
| IL319704A (en) * | 2022-09-23 | 2025-05-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of HBV gene expression |
| WO2024081879A1 (en) * | 2022-10-14 | 2024-04-18 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of cd247 expression |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| KR20250165443A (ko) | 2023-02-17 | 2025-11-25 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | 후성유전학적 변형 제조를 위한 조성물 및 방법 |
| WO2024238321A1 (en) * | 2023-05-12 | 2024-11-21 | Mammoth Biosciences, Inc. | Compositions and methods for targeted epigenetic modification |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024238700A1 (en) * | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| KR20260030105A (ko) * | 2023-06-16 | 2026-03-05 | 에피제닉 테라퓨틱스 피티이 리미티드 | B형 간염 바이러스 유전자를 표적으로 하는 후성유전학적 편집 도구 |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| WO2025059073A1 (en) | 2023-09-11 | 2025-03-20 | Tune Therapeutics, Inc. | Epigenetic editing methods and systems for differentiating stem cells |
| WO2025251019A1 (en) * | 2024-05-31 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| WO2025260068A1 (en) | 2024-06-14 | 2025-12-18 | Tune Therapeutics, Inc. | Lipid nanoparticle formulation for delivery of nucleic acids to cells |
| WO2026015647A1 (en) | 2024-07-09 | 2026-01-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1 |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10077453B2 (en) * | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US20190127713A1 (en) * | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| EP3463484B1 (en) * | 2016-05-27 | 2026-01-07 | The Regents of the University of California | Methods and compositions for targeting rna polymerases and non-coding rna biogenesis to specific loci |
| KR102922694B1 (ko) * | 2018-04-19 | 2026-02-03 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 유전자 편집을 위한 조성물 및 방법 |
-
2021
- 2021-06-01 AU AU2021283185A patent/AU2021283185A1/en active Pending
- 2021-06-01 US US17/999,756 patent/US20240309345A1/en active Pending
- 2021-06-01 JP JP2022574164A patent/JP2023529611A/ja active Pending
- 2021-06-01 EP EP21818236.8A patent/EP4158009A4/en active Pending
- 2021-06-01 CA CA3184884A patent/CA3184884A1/en active Pending
- 2021-06-01 MX MX2022015277A patent/MX2022015277A/es unknown
- 2021-06-01 WO PCT/US2021/035244 patent/WO2021247570A2/en not_active Ceased
- 2021-06-01 GB GB2506591.3A patent/GB2637278B/en active Active
- 2021-06-01 IL IL298434A patent/IL298434A/en unknown
- 2021-06-01 KR KR1020227044336A patent/KR20230031832A/ko active Pending
- 2021-06-01 GB GB2219607.5A patent/GB2612212B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4158009A2 (en) | 2023-04-05 |
| US20240309345A1 (en) | 2024-09-19 |
| GB2637278A (en) | 2025-07-16 |
| EP4158009A4 (en) | 2024-10-02 |
| WO2021247570A8 (en) | 2023-01-05 |
| GB202219607D0 (en) | 2023-02-08 |
| WO2021247570A2 (en) | 2021-12-09 |
| WO2021247570A3 (en) | 2022-03-24 |
| GB2612212B (en) | 2025-06-18 |
| GB2637278B (en) | 2025-11-05 |
| JP2023529611A (ja) | 2023-07-11 |
| GB202506591D0 (en) | 2025-06-11 |
| AU2021283185A1 (en) | 2023-01-05 |
| IL298434A (en) | 2023-01-01 |
| GB2612212A (en) | 2023-04-26 |
| CA3184884A1 (en) | 2021-12-09 |
| KR20230031832A (ko) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015277A (es) | Composiciones y metodos para la edicion de genes. | |
| MX2025005087A (es) | Composiciones y metodos para la edicion de genes | |
| PH12021551114A1 (en) | Crispr-cas12j enzyme and system | |
| PH12021550904A1 (en) | Novel crispr/cas12f enzyme and system | |
| WO2019191341A8 (en) | Nucleic acid-based therapeutics | |
| EP4471149A3 (en) | Type v crispr-cas base editors and methods of use thereof | |
| EP4431607A3 (en) | High-throughput precision genome editing | |
| WO2021067246A8 (en) | Deterministic barcoding for spatial omics sequencing | |
| EP4524148A3 (en) | Anti-vegf protein compositions and methods for producing the same | |
| MY208708A (en) | Nucleic acid constructs and methods of use | |
| IL288794A (en) | Targeted gene editing constructs and methods of using the same | |
| CL2023000554A1 (es) | Proteínas diseñadas y métodos de uso de las mismas. | |
| WO2021242793A3 (en) | Nucleic acid artificial mini-proteome libraries | |
| WO2020198174A8 (en) | Simultaneous multiplex genome editing in yeast | |
| WO2021203016A3 (en) | Protein-protein interaction stabilizers | |
| PH12022550460A1 (en) | Anti-cd96 antibodies and methods of use thereof | |
| WO2022034374A3 (en) | Improved gene editing | |
| EP3943512A4 (en) | FUSION PROTEIN TO ENHANCE GENE EDITING AND USE | |
| GB2600568A8 (en) | Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing | |
| WO2020237066A3 (en) | Gene editing in diverse bacteria | |
| MX2020011470A (es) | Metodos de terapia genica. | |
| WO2021248023A3 (en) | Compositions and methods for epigenome editing | |
| WO2023164670A3 (en) | Crispr-cas9 compositions and methods with a novel cas9 protein for genome editing and gene regulation | |
| CL2025002637A1 (es) | Proteínas de ingeniería y métodos de uso. | |
| MY198223A (en) | Cell Culture Medium For Eukaryotic Cells |